Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyridoxine for Levetiracetam-Induced Behavioral Adverse Events
NCT05008354Phase 4Completed
- Sponsor
- Dermaliq
- Start
- Oct 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of pyridoxine in adverse drug reaction (ADR), sponsored by Dermaliq. Started Oct 2020; status: completed.
02
Drugs
pyridoxine
03
Conditions
adverse drug reaction (ADR)
Beyond the preview
Go deeper on NCT05008354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05008354.